

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-34. (canceled)

35. (Currently amended) A ~~preparation as set forth in claim 31, further comprising a hemostasis protein pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a homeostasis protein, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.~~

36. (previously presented) A preparation as set forth in claim 35, wherein said hemostasis protein is a blood factor.

37. (previously presented) A preparation as set forth in claim 36, wherein said blood factor is selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, and blood factors with factor VIII inhibitor bypassing activity.

38-40. (canceled)

41. (currently amended) A ~~preparation as set forth in claim 31, further comprising a phospholipids pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a phospholipids, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.~~

42-65. (canceled)

66. (currently amended) A ~~preparation as set forth in claim 31, further comprising at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component and a phospholipids pharmaceutical~~

preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component and a phospholipids, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

67-78. (canceled)